{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T22:57:41Z","timestamp":1780959461126,"version":"3.54.1"},"reference-count":44,"publisher":"Japan Atherosclerosis Society","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAT","J Atheroscler Thromb"],"published-print":{"date-parts":[[2025,11,1]]},"DOI":"10.5551\/jat.65624","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T18:09:28Z","timestamp":1743790168000},"page":"1375-1389","source":"Crossref","is-referenced-by-count":4,"title":["Multilevel Factors Predict Medication Adherence and Efficacy within 12 Months in Patients Receiving PCSK9 Monoclonal Antibodies: The Findings from a Real-World Analysis in China"],"prefix":"10.5551","volume":"32","author":[{"given":"Xiaomeng","family":"Zheng","sequence":"first","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Ningbo University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyi","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Ningbo University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Ningbo University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanbin","family":"Cui","sequence":"additional","affiliation":[{"name":"Ningbo Clinical Research Center for Cardiovascular Disease (Grant No 2022L001)"},{"name":"Key Laboratory of Precision Medicine for Atherosclerotic Diseases of Zhejiang Province, The First Affiliated Hospital of Ningbo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suyan","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Ningbo University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3489","reference":[{"key":"1","unstructured":"1) Center For Cardiovascular Diseases The Writing Committee Of The Report On Cardiovascular Health And Diseases In China N: Report on Cardiovascular Health and Diseases in China 2023: An Updated Summary. Biomed Environ Sci, 2024; 37: 949-992"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Chapman FA, Maguire JJ, Newby DE, Davenport AP, Dhaun N: Targeting the apelin system for the treatment of cardiovascular diseases. Cardiovasc Res, 2023; 119: 2683-2696","DOI":"10.1093\/cvr\/cvad171"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Packard C, Chapman MJ, Sibartie M, Laufs U, Masana L: Intensive low-density lipoprotein cholesterol lowering in cardiovascular disease prevention: opportunities and challenges. Heart, 2021; 107: 1369-1375","DOI":"10.1136\/heartjnl-2020-318760"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L, Blumenthal R, Danesh J, Smith GD, DeMets D, Evans S, Law M, MacMahon S, Martin S, Neal B, Poulter N, Preiss D, Ridker P, Roberts I, Rodgers A, Sandercock P, Schulz K, Sever P, Simes J, Smeeth L, Wald N, Yusuf S, Peto R: Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet, 2016; 388: 2532-2561","DOI":"10.1016\/S0140-6736(16)31357-5"},{"key":"5","unstructured":"5) Vrints C, Andreotti F, Koskinas KC, Rossello X, Adamo M, Ainslie J, Banning AP, Budaj A, Buechel RR, Chiariello GA, Chieffo A, Christodorescu RM, Deaton C, Doenst T, Jones HW, Kunadian V, Mehilli J, Milojevic M, Piek JJ, Pugliese F, Rubboli A, Semb AG, Senior R, Ten Berg JM, Van Belle E, Van Craenenbroeck EM, Vidal-Perez R, Winther S; ESC Scientific Document Group: 2024 ESC Guidelines for the management of chronic coronary syndromes. Eur Heart J, 2024; 45: 3415-3537"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Chen L, Chen S, Bai X, Su M, He L, Li G, He G, Yang Y, Zhang X, Cui J, Xu W, Song L, Yang H, He W, Zhang Y, Li X, Hu S: Low-Density Lipoprotein Cholesterol, Cardiovascular Disease Risk, and Mortality in China. JAMA Netw Open, 2024; 7: e2422558","DOI":"10.1001\/jamanetworkopen.2024.22558"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Gitt AK, Lautsch D, Ferri\u00e8res J, De Ferrari GM, Vyas A, Baxter CA, Bash LD, Ashton V, Horack M, Almahmeed W, Chiang FT, Poh KK, Brudi P, Ambegaonkar B: Contemporary data on treatment practices for low-density lipoprotein cholesterol in 3867 patients who had suffered an acute coronary syndrome across the world. Data Brief, 2017; 16: 369-375","DOI":"10.1016\/j.dib.2017.11.034"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen MR, Tokgozoglu L, Wiklund O; ESC Scientific Document Group: 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J, 2020; 41: 111-188","DOI":"10.15829\/1560-4071-2020-3826"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Koren MJ, Sabatine MS, Giugliano RP, Langslet G, Wiviott SD, Ruzza A, Ma Y, Hamer AW, Wasserman SM, Raal FJ: Long-Term Efficacy and Safety of Evolocumab in Patients with Hypercholesterolemia. J Am Coll Cardiol, 2019; 74: 2132-2146","DOI":"10.1016\/j.jacc.2019.08.1024"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, Bisch JA, Richardson T, Jaros M, Wijngaard PLJ, Kastelein JJP; ORION-10 and ORION-11 Investigators: Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. N Engl J Med, 2020; 382: 1507-1519","DOI":"10.1056\/NEJMoa1912387"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Zhang M, Deng Q, Wang L, Huang Z, Zhou M, Li Y, Zhao Z, Zhang Y, Wang L: Prevalence of dyslipidemia and achievement of low-density lipoprotein cholesterol targets in Chinese adults: A nationally representative survey of 163,641 adults. Int J Cardiol, 2018; 260: 196-203","DOI":"10.1016\/j.ijcard.2017.12.069"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Mazhar F, Hjemdahl P, Clase CM, Johnell K, Jernberg T, Sj\u00f6lander A, Carrero JJ: Intensity of and Adherence to Lipid-Lowering Therapy as Predictors of Major Adverse Cardiovascular Outcomes in Patients with Coronary Heart Disease. J Am Heart Assoc, 2022; 11: e025813","DOI":"10.1161\/JAHA.122.025813"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Bradley CK, Shrader P, Sanchez RJ, Peterson ED, Navar AM: The patient journey with proprotein convertase subtilisin\/kexin type 9 inhibitors in community practice. J Clin Lipidol, 2019; 13: 725-734","DOI":"10.1016\/j.jacl.2019.06.008"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Liang Z, Chen Q, Yang F, Yan X, Zhang X, Chen X, Fang F, Zhao Q: Cost-Effectiveness of Evolocumab Therapy for Myocardial Infarction: The Chinese Healthcare Perspective. Cardiovasc Drugs Ther, 202; 35: 775-785","DOI":"10.1007\/s10557-020-07079-6"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Karve S, Cleves MA, Helm M, Hudson TJ, West DS, Martin BC: Good and poor adherence: optimal cut-point for adherence measures using administrative claims data. Curr Med Res Opin, 2009; 25: 2303-2310","DOI":"10.1185\/03007990903126833"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Yang Q, Chang A, Ritchey MD, Loustalot F: Antihypertensive Medication Adherence and Risk of Cardiovascular Disease Among Older Adults: A Population-Based Cohort Study. J Am Heart Assoc, 2017; 6: e006056","DOI":"10.1161\/JAHA.117.006056"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW; ACC\/AHA Joint Committee Members: 2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 2022; 145: e895-e1032","DOI":"10.1161\/CIR.0000000000001063"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Hines DM, Rane P, Patel J, Harrison DJ, Wade RL: Treatment patterns and patient characteristics among early initiators of PCSK9 inhibitors. Vasc Health Risk Manag, 2018; 14: 409-418","DOI":"10.2147\/VHRM.S180496"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Takahashi Y, Morimoto T, Iekushi K, Arai H: A Medical Claims Database Study of Factors Associated with Medication Adherence and Treatment Persistence in Patients Receiving PCSK9 Monoclonal Antibodies. J Atheroscler Thromb, 2025; 32: 163-175","DOI":"10.5551\/jat.64848"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Ray KK, Dhalwani N, Sibartie M, Bridges I, Ebenbichler C, Perrone-Filardi P, Villa G, Vogt A, Bruckert E: Low-density lipoprotein cholesterol levels exceed the recommended European threshold for PCSK9i initiation: lessons from the HEYMANS study. Eur Heart J Qual Care Clin Outcomes, 2022; 8: 447-460","DOI":"10.1093\/ehjqcco\/qcac009"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Gargiulo P, Basile C, Cesaro A, Marzano F, Buonocore D, Asile G, Abbate V, Vicidomini F, Paolillo S, Spaccarotella CAM, Catalano A, Spirito G, Merlini PA, Maloberti A, Iannuzzo G, Ciccone MM, Zito AP, Paloscia L, D\u2019Alleva A, Varbella F, Corleto A, Brunetti ND, Corbo MD, Calabr\u00f2 P, Indolfi C, Perrone-Filardi P: Efficacy, safety, adherence and persistence of PCSK9 inhibitors in clinical practice: A single country, multicenter, observational study (AT-TARGET-IT). Atherosclerosis, 2023; 366: 32-39","DOI":"10.1016\/j.atherosclerosis.2023.01.001"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Gupta M, Wani RJ, Al Faraidy K, Bergeron J, Contreras E, Pe\u00f1a AAG, Mancini GBJ, Padilla F, Lopez AAP, Philip K, Wu J, Mackinnon ES: Real-World Insights into Evolocumab Use in Patients with Hyperlipidemia Across Five Countries: Analysis from the ZERBINI Study. Cardiol Ther, 2023; 12: 703-722","DOI":"10.1007\/s40119-023-00334-5"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Lin PL, Wu YW, Lin CF, Yeh HI, Chang WT, Charng MJ, Huang PH, Lin CC, Lin TH, Lin WW, Hsieh IC, Kuo FY, Chen CP, Li YH: Real-World Analyses of the Treatment Conditions in Patients Initiating Proprotein Convertase Subtilisin\/Kexin Type 9 (PCSK9) Inhibitor in Taiwan. J Atheroscler Thromb, 2023; 30: 1123-1131","DOI":"10.5551\/jat.63789"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Li Y, Yang Y, Yuan J, Huang L, Ma Y, Shi X: Differences in medical costs among urban lung cancer patients with different health insurance schemes: a retrospective study. BMC Health Serv Res, 2022; 22: 612","DOI":"10.1186\/s12913-022-07957-9"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Farah RI, Alawwa IA, Khateeb DQ, Hwidi BE, Albdour KM, Bani Monia OG, Assaf RN, Aldabaibah AA, Alsaket GIJ, Alshrouf MA: Factors Affecting the Level of Adherence to Hypertension Medications: A Cross-Sectional Study Using the Hill-Bone Questionnaire. Patient Prefer Adherence, 2024; 18: 893-904","DOI":"10.2147\/PPA.S457026"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Cho SJ, Kim J: Factors associated with nonadherence to antihypertensive medication. Nurs Health Sci, 2014; 16: 461-467","DOI":"10.1111\/nhs.12145"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Plaza-Zamora J, Legaz I, Osuna E, P\u00e9rez-C\u00e1rceles MD: Age and education as factors associated with medication literacy: a community pharmacy perspective. BMC Geriatr, 2020; 20: 501","DOI":"10.1186\/s12877-020-01881-5"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Xu M, Zhang D, Yang M, Wu W: Factors influencing safe use of drugs among community residents: a cross-sectional study. BMC Public Health, 2024; 24: 2373","DOI":"10.1186\/s12889-024-19911-x"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Su Y, Wang X, Xing Y, Wang Z, Bu H, Cui X, Yang Y, Cai B: The analysis of factors affecting medication adherence in patients with myasthenia gravis: a cross-sectional study. Ther Adv Neurol Disord, 2024; 17: 17562864231206877","DOI":"10.1177\/17562864231206877"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Simon ST, Kini V, Levy AE, Ho PM: Medication adherence in cardiovascular medicine. BMJ, 2021; 374: n1493","DOI":"10.1136\/bmj.n1493"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Kini V, Ho PM: Interventions to Improve Medication Adherence: A Review. JAMA, 2018; 320: 2461-2473","DOI":"10.1001\/jama.2018.19271"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Gayoso-Rey M, D\u00edaz-Trastoy O, Romero-Ventosa EY, Garc\u00eda-Beloso N, Gonz\u00e1lez-Freire L, Lorenzo-Lorenzo K, Manti\u00f1\u00e1n-Gil B, Palmeiro-Carballeira R, Bravo-Amaro M, L\u00f3pez-Gil-Otero MDM, Mart\u00ednez-Reglero C, Crespo-Diz C, Fern\u00e1ndez-Catalina P, Pi\u00f1eiro Corrales G: Effectiveness, Safety, and Adherence to Treatment of Proprotein Convertase Subtilisin\/Kexin Type 9 Inhibitors in Real Practice. Clin Ther, 2021; 43: e111-e121","DOI":"10.1016\/j.clinthera.2021.02.002"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Rallidis LS, Skoumas I, Liberopoulos EN, Vlachopoulos C, Kiouri E, Koutagiar I, Anastasiou G, Kosmas N, Elisaf MS, Tousoulis D, Iliodromitis E: PCSK9 inhibitors in clinical practice: Novel directions and new experiences. Hellenic J Cardiol, 2020; 61: 241-245","DOI":"10.1016\/j.hjc.2019.10.003"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Zafrir B, Jubran A: Lipid-lowering therapy with PCSK9-inhibitors in the real-world setting: Two-year experience of a regional lipid clinic. Cardiovasc Ther, 2018; 36: e12439","DOI":"10.1111\/1755-5922.12439"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Lin I, Sung J, Sanchez RJ, Mallya UG, Friedman M, Panaccio M, Koren A, Neumann P, Menzin J: Patterns of Statin Use in a Real-World Population of Patients at High Cardiovascular Risk. J Manag Care Spec Pharm, 2016; 22: 685-698","DOI":"10.18553\/jmcp.2016.22.6.685"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) D\u2019Ascenzo F, Biol\u00e8 C, Raposeiras-Roubin S, Gaido F, Abu-Assi E, Kinnaird T, Ariza-Sol\u00e9 A, Liebetrau C, Manzano-Fern\u00e1ndez S, Boccuzzi G, Henriques JPS, Templin C, Wilton SB, Omed\u00e8 P, Velicki L, Xanthopoulou I, Correia L, Cerrato E, Rognoni A, Fabrizio U, Nu\u00f1ez-Gil I, Montabone A, Taha S, Fujii T, Durante A, Song X, Gili S, Magnani G, Autelli M, Bongiovanni F, Grosso A, Kawaji T, Blanco PF, Garay A, Quadri G, Alexopoulos D, Queija BC, Huczek Z, Paz RC, Gonz\u00e1lez-Juanatey JR, Fern\u00e1ndez MC, Nie SP, Pousa IM, Kawashiri MA, Rettegno S, Gallo D, Morbiducci U, Conrotto F, Dominguez-Rodriguez A, Vald\u00e9s M, Cequier A, I\u00f1iguez-Romo A, Biondi-Zoccai G, Stone GW, De Ferrari GM: Average daily ischemic versus bleeding risk in patients with ACS undergoing PCI: Insights from the BleeMACS and RENAMI registries. Am Heart J, 2020; 220: 108-115","DOI":"10.1016\/j.ahj.2019.10.001"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Khunti K, Danese MD, Kutikova L, Catterick D, Sorio-Vilela F, Gleeson M, Kondapally Seshasai SR, Brownrigg J, Ray KK: Association of a Combined Measure of Adherence and Treatment Intensity With Cardiovascular Outcomes in Patients With Atherosclerosis or Other Cardiovascular Risk Factors Treated With Statins and\/or Ezetimibe. JAMA Netw Open, 2018; 1: e185554","DOI":"10.1001\/jamanetworkopen.2018.5554"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) De Luca L, Arca M, Temporelli PL, Colivicchi F, Gonzini L, Lucci D, Bosco B, Callerame M, Lettica GV, Di Lenarda A, Gulizia MM; START Investigators: Prevalence and pharmacologic management of familial hypercholesterolemia in an unselected contemporary cohort of patients with stable coronary artery disease. Clin Cardiol, 2018; 41: 1075-1083","DOI":"10.1002\/clc.23031"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Faggiano P, Pirillo A, Griffo R, Ambrosetti M, Pedretti R, Scorcu G, Werren M, Febo O, Malfatto G, Favretto G, Sarullo F, Antonini-Canterin F, Zobbi G, Temporelli P, Catapano AL; Centro Studi e Formazione - Italian Association for Cardiovascular Prevention and Rehabilitation: Prevalence and management of familial hypercholesterolemia in patients with coronary artery disease: The heredity survey. Int J Cardiol, 2018; 252: 193-198","DOI":"10.1016\/j.ijcard.2017.10.105"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Mortensen MB, Kulenovic I, Klausen IC, Falk E: Familial hypercholesterolemia among unselected contemporary patients presenting with first myocardial infarction: Prevalence, risk factor burden, and impact on age at presentation. J Clin Lipidol, 2016; 10: 1145-1152","DOI":"10.1016\/j.jacl.2016.06.002"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41) Shi HW, Yang JG, Wang Y, Li W, Guo YL, Gao Y, Tang YD, Li JJ, Wu NQ, Yang YJ: The Prevalence of Familial Hypercholesterolemia (FH) in Chinese Patients With Acute Myocardial Infarction (AMI): Data From Chinese Acute Myocardial Infarction (CAMI) Registry. Front Cardiovasc Med, 2020; 7: 113","DOI":"10.3389\/fcvm.2020.00113"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) Cross AJ, Elliott RA, Petrie K, Kuruvilla L, George J: Interventions for improving medication-taking ability and adherence in older adults prescribed multiple medications. Cochrane Database Syst Rev, 2020; 5: CD012419","DOI":"10.1002\/14651858.CD012419.pub2"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Bossie CA, Alphs LD, Correll CU: Long-acting injectable versus daily oral antipsychotic treatment trials in schizophrenia: pragmatic versus explanatory study designs. Int Clin Psychopharmacol, 2015; 30: 272-281","DOI":"10.1097\/YIC.0000000000000082"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44) Piccinni C, Antonazzo IC, Maggioni AP, Pedrini A, Calabria S, Ronconi G, Dondi L, Martini N, Roberto G, Sampietro T, Sbrana F, Pino BD, Bigazzi F, Surdo GL, Volpi E, Biagini S, Gini R: PCSK9 Inhibitors\u2019 New Users: Analysis of Prescription Patterns and Patients\u2019 Characteristics from an Italian Real-world Study. Clin Drug Investig, 2020; 40: 173-181","DOI":"10.1007\/s40261-019-00877-3"}],"container-title":["Journal of Atherosclerosis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/32\/11\/32_65624\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T04:17:28Z","timestamp":1761970648000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/32\/11\/32_65624\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,1]]},"references-count":44,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.5551\/jat.65624","relation":{},"ISSN":["1340-3478","1880-3873"],"issn-type":[{"value":"1340-3478","type":"print"},{"value":"1880-3873","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,1]]},"article-number":"65624"}}